T-cell-directed therapies in inflammatory bowel diseases.
about
Haemophagocytic lymphohistiocytosis in inflammatory bowel disease with virus infectionPrevention of colitis-associated cancer: natural compounds that target the IL-6 soluble receptorMolecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseasesBifidobacterium breve attenuates murine dextran sodium sulfate-induced colitis and increases regulatory T cell responsesPathways analysis of molecular markers in chronic sinusitis with polyps.Distinct profiles of effector cytokines mark the different phases of Crohn's diseaseCurrent and emerging drugs for the treatment of inflammatory bowel disease.Anti-Adhesion Therapies in Inflammatory Bowel Disease-Molecular and Clinical Aspects.Azathioprine with Allopurinol: Lower Deoxythioguanosine in DNA and Transcriptome Changes Indicate Mechanistic Differences to Azathioprine Alone.B cells secrete eotaxin-1 in human inflammatory bowel disease.The TRPA1 ion channel is expressed in CD4+ T cells and restrains T-cell-mediated colitis through inhibition of TRPV1.Role of IL-21 in inflammatory bowel disease.Molecular and Cellular Mechanisms Involved in Mesenchymal Stem Cell-Based Therapy of Inflammatory Bowel Diseases.Intestinal T cell profiling in Inflammatory Bowel Disease; linking T cell subsets to disease activity and disease course.Role of DOR-β-arrestin1-Bcl2 signal transduction pathway and intervention effects of oxymatrine in ulcerative colitis.Allele-specific DNA methylation of disease susceptibility genes in Japanese patients with inflammatory bowel disease.[A novel role for the TRPV1 ion channel in CD4 T cell activation].
P2860
Q26777669-2E084980-9ECE-4D36-A8C5-C116BC29B6AAQ27022976-234DC2D2-E70A-48A7-9170-37C7775D8941Q28067245-89B2D604-D14F-4CD1-85DB-4C9E7FF35129Q33559718-EB169E24-0B3F-4AEF-87B4-1863BC0FDD91Q33873144-369791D9-C3C2-4441-BC0F-3327CF06923FQ34563301-37B57BCC-AC4D-4161-81CB-B68048079C16Q34883210-D48E9F68-7006-4628-B8B6-CF763C920F8AQ38643163-A81C1F87-4FFB-466D-A32F-233146AEA892Q42257605-77902E62-C0EE-4FC6-914C-E519CBC1B716Q42270278-B4E2D26A-ED20-45C8-B529-E97F950BA31EQ46835576-EA7DB47B-0CF5-4DBD-8BE3-CF963A8E2F99Q46987803-1C3B3219-6695-453C-AAFE-13C5EC4264F1Q48234353-1FFB925F-52E1-4296-9113-7C373274E8ECQ50049064-055B50E7-DF31-466F-B845-7940D7DE7E59Q51311354-896579F3-8788-4400-B653-F12D8896E4BFQ52726132-12B80A66-4664-4FF4-B1DB-68EBE69979F3Q54286419-E1A91CD3-674B-4A2E-882C-DF8A815A507B
P2860
T-cell-directed therapies in inflammatory bowel diseases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
T-cell-directed therapies in inflammatory bowel diseases.
@en
T-cell-directed therapies in inflammatory bowel diseases.
@nl
type
label
T-cell-directed therapies in inflammatory bowel diseases.
@en
T-cell-directed therapies in inflammatory bowel diseases.
@nl
prefLabel
T-cell-directed therapies in inflammatory bowel diseases.
@en
T-cell-directed therapies in inflammatory bowel diseases.
@nl
P2860
P356
P1433
P1476
T-cell-directed therapies in inflammatory bowel diseases
@en
P2093
Giovanni Monteleone
P2860
P304
P356
10.1042/CS20100027
P407
P577
2010-03-30T00:00:00Z